Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

• Alnylam Pharmaceuticals, Inc. recently announced a $1 billion share repurchase program, a corporate action where a company buys back its own shares from the open market, which signals management's confidence in the company's future value and can reduce the number of shares outstanding to potentially increase earnings per share.
• The company presented five-year data from the HELIOS-B trial at the American Heart Association Scientific Sessions 2026, demonstrating that earlier treatment with AMVUTTRA (vutrisiran) cuts the risk of death and heart events in patients with transthyretin amyloidosis with cardiomyopathy, providing robust long-term clinical evidence for its lead product.
• Alnylam Pharmaceuticals, Inc. reported a significant earnings beat in its most recent quarter, posting $16.26 in earnings per share compared to analyst consensus estimates of $1.66, indicating strong profitability and operational efficiency that exceeded market expectations.
• The stock is currently trading at $156.61, which is near its 52-week low of $152.17, offering a potential entry point for investors given that the company maintains a low beta of 0.42, suggesting lower volatility compared to the broader market.
• Institutional interest remains strong, with Pictet Asset Management Holding SA increasing its stake by 77.7% in the third quarter, and the company maintains a high institutional ownership percentage of 92.97%, reflecting confidence from major financial entities.